Eliem Therapeutics

Eliem Therapeutics is a biopharmaceutical company dedicated to addressing unmet needs in psychiatry, epilepsy, chronic pain, and other disorders related to neuronal excitability. The company’s pipeline features ETX-155, which is being developed for major depressive disorder and focal onset seizures, and is set to initiate Phase 2a trials. Eliem Therapeutics employs clinically validated mechanisms in its drug development processes and is engaged in both clinical and preclinical stages targeting conditions of the central and peripheral nervous system. The company has successfully raised $60 million in Series B financing and an additional $92 million through an initial public offering (IPO) to advance its clinical programs. However, it discontinued the ETX-810 program after failing to meet primary endpoints in clinical trials. Recently, Eliem announced plans to explore strategic alternatives to maximize shareholder value.